Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis

Objective To perform a meta-analysis of migraine biomarkers in cerebrospinal fluid (CSF) and of corresponding blood concentrations. Methods We conducted a systematic search for studies that measured biochemical compounds in CSF of chronic or episodic migraineurs and non-headache controls. Subsequent...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cephalalgia Ročník 37; číslo 1; s. 49
Hlavní autoři: van Dongen, Robin M, Zielman, Ronald, Noga, Marek, Dekkers, Olaf M, Hankemeier, Thomas, van den Maagdenberg, Arn Mjm, Terwindt, Gisela M, Ferrari, Michel D
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 01.01.2017
Témata:
Biomarkers - blood
Biomarkers - cerebrospinal fluid
Case-Control Studies
Cross-Over Studies
Humans
Intercellular Signaling Peptides and Proteins - blood
Intercellular Signaling Peptides and Proteins - cerebrospinal fluid
Migraine Disorders - blood
Migraine Disorders - cerebrospinal fluid
Migraine Disorders - diagnosis
Neuropeptides - blood
Neuropeptides - cerebrospinal fluid
meta-analysis
Migraine
biomarkers
cerebrospinal fluid
ISSN:1468-2982, 1468-2982
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Objective To perform a meta-analysis of migraine biomarkers in cerebrospinal fluid (CSF) and of corresponding blood concentrations. Methods We conducted a systematic search for studies that measured biochemical compounds in CSF of chronic or episodic migraineurs and non-headache controls. Subsequent searches retrieved studies with blood measurements of selected CSF biomarkers. If a compound was assessed in three or more studies, results were pooled in a meta-analysis with standardised mean differences (SMD) as effect measures. Results Sixty-two compounds were measured in 40 CSF studies. Most important results include: increased glutamate (five studies, SMD 2.22, 95% CI: 1.30, 3.13), calcitonin gene-related peptide (CGRP) (three studies, SMD: 3.80, 95% CI: 3.19, 4.41) and nerve growth factor (NGF) (three studies, SMD: 6.47, 95% CI: 5.55, 7.39) in chronic migraine patients and decreased β-endorphin (β-EP) in both chronic (four studies, SMD: -1.37, 95% CI: -1.80, -0.94) and interictal episodic migraine patients (three studies, SMD: -1.12, 95% CI: -1.65, -0.58). In blood, glutamate (interictal) and CGRP (chronic, interictal and ictal) were increased and β-EP (chronic, interictal and ictal) was decreased. Conclusions Glutamate, β-EP, CGRP and NGF concentrations are altered in CSF and, except for NGF, also in blood of migraineurs. Future research should focus on the pathophysiological roles of these compounds in migraine.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
ISSN:1468-2982
1468-2982
DOI:10.1177/0333102415625614